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Abstract
Background: This study was designed to evaluate the safety of PolyGlycopleX® (PGX®), a novel
viscous dietary polysaccharide (fiber), when administered to Sprague Dawley® rats in the diet for
90 days.
Methods: Groups of ten male and ten female rats each consumed PGX mixed in the diet at levels
of 0, 1.25, 2.5 or 5.0% for 90 days, then evaluated for toxicological effects on parameters that
included neuromotor activity, body weight, clinical chemistry, urinalysis, hematology, and
histopathology.
Results: Mean body weight, mean feed consumption and food efficiency in the treated groups were
generally comparable to controls for both male and female rats. No changes were noted in
neuromotor behavior, and histopathological analysis revealed no significant changes between
treated and control animals. There were no differences in mean organ weight, organ-to-body
weight or organ-to-brain weight values between controls and treated animals. Decreased red
blood cell count occurred in the high dose males and increases in aspartate and alanine
aminotransferase enzyme levels and triglycerides, while significant decreases in serum sodium,
potassium and chloride concentrations were observed in the females fed 5.0% PGX. However, the
decreased mineral concentrations may be the result of significantly increased urinary volume in
both males and females at the high dose, with a concomitant decrease in urinary specific gravity
(males and females) and protein concentration (females). These results were within historical
control values, did not correlate with any histopathological changes, and were not considered
adverse.
Conclusion: The results indicate a no observed adverse effect level (NOAEL) for PGX at 5.0% of
the diet, corresponding to an average daily intake of 3219 and 3799 mg/kg bw/day in male and
female rats, respectively.
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Background
Dietary fiber has been declared a nutrient under the Nutri-
tion Labeling and Education Act of 1990, for the purposes
of nutrition labelling. The Institute of Medicine [1] states
that "Dietary fiber consists of nondigestible food plant
carbohydrates and lignin in which the plant matrix is
largely intact. Nondigestible means that the material is
not digested and absorbed in the human small intestine."
Dietary fibers are defined as either soluble or insoluble
(depending on solubility characteristics), and fermenta-
ble or non-fermentable, depending on the ability of
anaerobic bacteria in the colon to digest the fiber. This
definition encompasses a broad category of carbohy-
drates, including cellulosic plant material, pectins, gums,
and non-plant (e.g., animal or fungal) dietary substances.
Many positive benefits have been associated with diets
rich in fiber, including a reduced risk of diabetes and car-
diovascular disease, reduced risk of hypertension, as well
as a reduction of total and low density lipoprotein (LDL)
cholesterol [2] and an increase in high density lipoprotein
(HDL) cholesterol [3-6]. The type of fiber may affect food
consumption, as some fibers have the ability to swell and
hold water, inducing a feeling of fullness [7], which can
aid in the maintenance of, or a reduction in, body weight.
In the United States, most people consume less fiber than
the daily value recommendation of 25 g. Food manufac-
turers have started evaluating the combination of specific
fiber types to produce a complex fiber food ingredient that
may provide the positive benefits of fiber, without com-
promising on taste or texture. PGX is a proprietary product
manufactured from glucomannan (prepared from konjac
powder), sodium alginate, and xanthan gum. Glucoman-
nan, a β-D-(1-4)-linked linear polymer of glucose and
mannose substituted with O-acetate every 9 to 19 sugar
units [8], produces a viscous fiber that is highly fermenta-
ble in the large intestine. Alginates are algal polysaccha-
rides that are used in the food industry as stabilizers or
thickening agents. Xanthan gum, a polysaccharide pro-
duced by the bacterium Xanthomonas campestris, has a vis-
cous property that adds bulk and increases stool water
retention. Both the gum and the alginate are also consid-
ered viscous, indigestible dietary fibers, shown to lower
the rate of small intestinal absorption of metabolizable
nutrients and may potentially decrease caloric intake from
the small intestine [9-11]. Although each of these fibers
has been studied for their safety when used alone or with
other fibers, this unique product, formed from the combi-
nation of fibers, has not been evaluated. Therefore, this
study was designed to assess the safety of subchronic
administration of PGX to male and female Sprague Daw-
ley® rats.
Methods
The study was conducted at Eurofins|Product Safety Lab-
oratories (Dayton, NJ) under the sponsorship of Inovo-
Biologic, Inc. (Calgary, Alberta).
Test Article
The composition of the test article is that of a granular
powder produced and marketed under the trade name
PGX® (InovoBiologic, Inc., Calgary, Alberta), an off-white
powder soluble in water, that has been manufactured
from glucomannan, xanthan gum and sodium alginate by
a proprietary process. PGX was added to PMI LabDiet®
Certified Rodent Meal #5002 and mixed for 20 minutes at
room temperature to form a homogeneous mixture. The
vehicle diet was mixed under the same conditions. The
diets were prepared once per week and refrigerated until
use. The dietary concentration was 0, 12,500, 25,000, and
50,000 ppm, corresponding to 0, 1.25, 2.5, and 5.0% in
the diet.
Animals
Sprague Dawley® rats (ten/sex/group) were supplied from
Harlan, Inc. (Indianapolis, IN), and were seven to eight
weeks of age at the beginning of the study. The animals
were housed singly in an animal room with a 12-hour
light/dark cycle at a temperature and relative humidity
range of 22 ± 3°C and 30–70%, respectively. The animals
were acclimated for at least five days prior to testing. PMI
LabDiet® Certified Rodent Diet Meal #5002 was available
ad libitum during the acclimation period. Water was avail-
able ad libitum throughout the study.
Study Design
This study was conducted based on OECD Guidelines for
Testing of Chemicals, Section 4 (Part 408): Health Effects
(1987) and US FDA Redbook 2000, IV.C.3a. "Short-term
toxicity studies with rodents" (2003). It also complied
with OECD Principles of Good Laboratory Practices [12]
and US FDA Good Laboratory Practices [13]. All work
undertaken by the testing laboratory was in accordance
with the most recent Guide for the Care and Use of Labora-
tory Animals [14], and the laboratory received accredita-
tion from the Council on Accreditation of the Association
for Assessment and Accreditation of Laboratory Animal
Care (AAALAC International) and approval from the
National Institutes of Health Office of Laboratory Animal
Welfare (OLAW) for animal experimentation. Briefly, four
groups of twenty rats (ten/sex/group) were each provided
a diet containing 0, (Group 1), 12,500 ppm (1.25%,
Group 2), 25,000 ppm (2.5%, Group 3), or 50,000 ppm
(5%, Group 4) PGX for 92 days (13 weeks). The animals
were observed daily for viability, behavioral changes and
signs of gross toxicity, and weekly for a battery of detailed
observations. Individual food consumption was recorded
weekly. Mean daily food consumption was calculated forNutrition Journal 2009, 8:1 http://www.nutritionj.com/content/8/1/1
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each sex/dietary level at each week and for the overall
(Days 1 to 92) testing interval. The Group mean daily
intake of test article was calculated by multiplying the
Group mean daily food consumption (grams) for a given
interval by dose concentration and then dividing by the
Group mean body weight (grams) for a given interval.
Mean daily food efficiency was also calculated for each
sex/dietary level based on body weight gain and daily
food consumption data. Body weights were recorded two
times during the acclimation period, prior to test initia-
tion (Day 1), weekly during the study, and just prior to
terminal sacrifice. Mean daily body weight gains were cal-
culated for each sex/dietary level at each interval and for
the overall testing interval (Days 1–94). A Functional
Observational Battery (FOB) and a Motor Activity (MA)
test were performed on all animals during Week 12 of the
study. Included in this evaluation were observations while
the rat was in the home cage, as well as open field obser-
vations. These observations included both forelimb and
hindlimb grip strength, as well as hindlimb foot splay. A
clinical pathology analysis was conducted on samples col-
lected on test Day 87 for hematology, clinical chemistry,
and urinalysis, and on Days 93 (males) and 94 (females)
for coagulation.
Animals were fasted for at least 15 hours and then placed
in metabolism cages one day before clinical pathology
evaluation. Urine was collected from each animal and
analyzed for quality, pH, ketone, color, glucose, bilirubin,
clarity, specific gravity, blood, volume, protein, urobilino-
gen and microscopic urine sediment. Urine protein was
measured on an Olympus® AU640 clinical chemistry ana-
lyzer. Other urine constituents were semi-quantitatively
measured on a Bayer Clinitek® Atlas™ Automated Urine
Chemistry analyzer (Siemens Medical Solutions Diagnos-
tics, Tarrytown, NY). Sediments from all urine specimens
were evaluated microscopically.
Animals were fasted overnight and blood samples were
collected for hematology (except prothrombin and partial
thromboplastin time) and clinical chemistry via orbital
sinus bleeding under isoflurane anesthesia on Day 87 of
the study. Blood samples for determination of pro-
thrombin time and activated partial thromboplastin time
were taken via  the inferior vena cava under isoflurane
anesthesia prior to terminal sacrifice on Day 93 (males) or
Day 94 (females).
Hematology parameters included erythrocyte count,
hemoglobin concentration, hematocrit, mean corpuscu-
lar volume, mean corpuscular hemoglobin, red cell distri-
bution width, absolute reticulocyte count, platelet count,
total white blood cell and differential leukocyte count.
Mean corpuscular hemoglobin concentration was also
calculated. Blood smears were prepared and evaluated.
Complete blood counts, including reticulocytes, were
determined on a Bayer® Advia 120 hematology analyzer
(Diamond Diagnostics, Holliston, MA) or determined
from microscopic evaluation of the blood smear. Wright-
Giemsa-stained blood smears from all animals were
examined microscopically for confirmation of automated
results and evaluation of cellular morphology. Coagula-
tion times were determined on a Sysmex® CA-1000 Coag-
ulation Analyzer (Sysmex America, Inc., Mundelein, IL).
Clinical biochemistry values analyzed were: serum aspar-
tate aminotransferase, serum alanine aminotransferase,
sorbitol dehydrogenase, alkaline phosphatase, total
bilirubin, blood urea nitrogen, blood creatinine, total
cholesterol, triglycerides, fasting glucose, total serum pro-
tein, albumin, globulin, calcium, inorganic phosphorus,
sodium, potassium, and chloride. Serum clinical chemis-
try parameters were determined on an Olympus® AU640
clinical chemistry analyzer (Center Valley, PA). Serum
samples from two randomly chosen animals were pooled
and a viral screen was performed.
Gross necropsies were performed on all study rats at study
termination, and selected organs and tissues from the
control (Group 1) and high dose (Group 4) groups were
harvested, weighed, and evaluated for histological
changes (Table 1) following staining with hematoxylin
and eosin and examination by light microscopy.
In addition, gross lesions of potential toxicological signif-
icance noted in any test groups at time of euthanasia were
Table 1: Tissues collected at necropsy and microscopically evaluated in the control and high dose treatment groups
Lungs Trachea Thymus Heart
Sternum with bone marrow Adrenals Liver Spleen
Kidneys Thyroid/parathyroid Urinary bladder Ovaries uterus & fallopian tubes
Vagina Esophagus Ileum Cecum
Peripheral nerve (sciatic) Jejunum Stomach Duodenum
Accessory genital organs 
(prostate and seminal vesicles)
Colon Rectum Representative lymph node 
(mesenteric & mandibular)
Pancreas Pituitary Aorta Female mammary gland
Harderian gland Skin Nasal turbinates Skeletal muscle
Epididymides Testes EyesNutrition Journal 2009, 8:1 http://www.nutritionj.com/content/8/1/1
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also examined. These included the uterus and fallopian
tubes from two low dose and one intermediate dose
female(s) and the testes from one intermediate dose male.
Relative organ weights (g/kg body weight) were calculated
using terminal body weights.
Statistical Analysis
Statistical analysis of the in-life and organ weight data
[i.e., means and standard deviations of body weight, daily
body weight gain, daily food consumption, daily food
efficiency, organ weight, and organ-to-body/brain weight
ratio, and the functional observation battery (FOB)] were
initially evaluated for variance homogeneity and normal-
ity by Bartlett's test. When the variances were homogene-
ous, treated and control groups were compared using a
One-Way Analysis of Variance (ANOVA), followed by
comparison of the treated groups to control by Dunnett's
t-test for multiple comparisons. Otherwise, groups were
compared using a non-parametric method (Kruskal-Wal-
lis non parametric analysis of variance followed by
Dunn's test). Motor activity data was analyzed by Two-
Way repeated measures ANOVA. Means and standard
deviations were calculated for the quantitative clinical
pathology data using Levene's test, and the Shapiro-Wilk
test for normality. If variances were not significantly dif-
ferent, groups were compared using a One-Way Analysis
of Variance (ANOVA) followed by Dunnett's t-test for
multiple comparisons. If the Shapiro-Wilk test was not
significant but Levene's test was significant, a robust ver-
sion of Dunnett's test was utilized. When Levene's test
indicated significantly different variances, groups were
compared using a non-parametric method (Kruskal-Wal-
lis non parametric analysis of variance) followed by
Dunn's test. Male and female rats were evaluated sepa-
rately, and differences among groups were judged to be
significant at a probability value of P ≤ 0.05.
Results
The mean overall daily intake in male rats fed dietary con-
centrations of 0, 12,500, 25,000, and 50,000 ppm PGX
(equivalent to 0, 1.25, 2.5, and 5.0% of the diet, respec-
tively) during this study was approximately 0, 806, 1617,
and 3219 mg/kg bw/day, respectively. For the same die-
tary concentrations, female rats consumed a mean overall
daily intake of approximately 0, 918, 1828, and 3799 mg/
kg/day PGX, respectively. Mean daily food consumption
and food efficiency for all groups of male and female rats
that consumed 1.25, 2.5, or 5.0% PGX were comparable
with control values (Figure 1).
There were no mortalities during the study and all animals
appeared active and healthy during the course of the
study. Transient clinical signs included intermittent and
sporadic light brown feces for one intermediate group
female (Day 57), all high dose males (Days 57 and 64)
and 2/10 and 6/10 high dose females (Days 57 and 64,
respectively). These findings were considered non adverse
as all animals recovered by the end of the study. One high
dose male was found emaciated on Day 57, the result of a
faulty water valve, unrelated to test substance administra-
tion and data from this animal was removed from the
group averages for Days 57 and 64 for body weight and for
Days 57, 64, and 1–92 (overall) for parameters of body
weight gain, food consumption, food efficiency and mean
daily intake. One high dose female was noted with emaci-
ation and a reduced fecal volume during the detailed clin-
ical observations on Day 92. This animal had a reduced
body weight, body weight gain, food consumption and
feed efficiency during study Days 84–92. A noted reduc-
tion in absolute and relative thymus weight (necropsy
Day 94) was confirmed histologically as slight atrophy,
however, there were no clinical pathology findings associ-
ated with this animal and the cause for emaciation
remains undetermined pathologically. Due to their short
duration, limited severity and singular appearance in one
animal within the group, these findings were considered
incidental and not test article-related.
Weekly mean body weight and body weight gain for all
groups that consumed PGX were comparable to control
values (Figure 2). Both eyes of all the study rats were
examined by focal illumination and indirect ophthalmos-
copy prior to study initiation and on Day 88 of the study;
no treatment related effects were noted. The Functional
Observational Battery and Motor Activity tests conducted
in both the male and female rats that consumed PGX were
comparable to results from the control rats.
Male rats fed 5% PGX in the diet had a significant decrease
in red blood cell count at the end of the study (P < 0.05),
but this did not follow a dose-response effect and there
were no statistically significant effects in any other red cell
or coagulation parameters, and no hematological effects
in the female treatment groups. Analysis of the mean clin-
ical chemistry parameters found that male rats fed 5%
PGX in the diet showed a significant increase in the serum
albumin concentration (P  ≤ 0.05); however, no other
effects were noted in any of the remaining clinical chem-
istry parameters evaluated in the male rats at any PGX
treatment level (Table 2). In the female rats fed PGX at 5%
of the diet, significant increases were noted in mean aspar-
tate aminotransferase, alanine aminotransferase, and
serum triglyceride concentrations (Table 3). A significant
decrease in the inorganic phosphorous concentration was
found in the female rats fed 2.5% PGX, but not in the
5.0% or 1.25% dose groups. In female rats fed 5.0% PGX,
there were significant decreases in serum sodium, potas-
sium, and chloride levels (P ≤ 0.05). Serological study
showed no detectable titers against the pathogens and
antigens tested.Nutrition Journal 2009, 8:1 http://www.nutritionj.com/content/8/1/1
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Evaluation of urinalysis parameters found that urinary
volume was increased in both males and females fed 5.0%
PGX, while the specific gravity of the urine was decreased
at the highest dose level in both male and female rats
(Table 4). The protein content in the urine of female rats
administered 5.0% PGX in the diet was significantly
decreased compared to control animals. Urinary pH was
increased in male rats fed 2.5 and 5.0% PGX, and in
female rats fed 5.0% PGX.
At study termination the rats were euthanized, organs
removed, weighed, and histopathological analysis was
conducted. No gross abnormalities attributable to PGX
administration were found. Incidental findings included
fluid-filled uteri in some of the females in all groups (one
rat each in control and 2.5% treatment group, two rats
each in the 1.25 and 5.0% treatment groups, respectively),
and a light brown encapsulated firm mass, anteriomedial
of the right testis in one male fed 2.5% PGX, for which
there were no histological correlate. There were no differ-
ences between the control group and any test group in
mean organ weight (Table 5), as well as organ-to-body
weight and organ-to-brain weight (Table 6) in either
males or females. Histopathological analysis found that
all microscopic changes observed in the animals sacrificed
at study termination were of a type commonly observed in
control laboratory rats, and were of comparable incidence
in controls and high dose groups in this study.
Food consumption for male and female rats exposed for 90 days to PGX® Figure 1
Food consumption for male and female rats exposed for 90 days to PGX®. Values represent mean ± SD of 10 rats/
sex/group.
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Discussion
The composition, solubility, and viscosity of fibrous prod-
ucts classified as "nondigestible" may have various effects
on the absorption, metabolism, and excretion of ingested
material. Brown et al. [2] found that various soluble fibers
(e.g., oat, psyllium, or pectin fiber) reduce total and LDL
serum cholesterol in clinical studies, but did not affect tri-
acylglycerol and HDL cholesterol levels. Nondigestible
fibers are resistant to the action of salivary, intestinal, and
pancreatic hydrolases, but may be readily fermented by
bacteria in the cecum/large intestine, hydrolyzing to short
chain fatty acids (SCFA), thus releasing hydrogen and
other gases [1]. Several SCFA have been shown to have
anti-inflammatory properties and may have a beneficial
effect on inflammatory bowel disease in culture [15,16].
Viscous fibers have been found to alter blood glucose and
cholesterol concentrations, as well as prolonging gastric
emptying time and slowing transit time through the small
intestine [17-19]. Increased consumption of dietary vis-
cous fiber has also been shown to reduce serum glucose
increases during meal consumption, decrease plasma cho-
lesterol, and improve the colonic ecology in clinical trials
[9] and modify the absorption of fats, minerals and bile
acids as well as influence appetite and absorb toxins [20-
23].
PGX is manufactured from three different viscous dietary
fibers by a proprietary process: one fermentable β-glycan
fiber, an alginate, and a polysaccharide gum. Indigestible
carbohydrates such as alginates and gums are not digested
in the small intestine, but pass into the large intestine
where the bacterial flora ferment these fibers (β-glycan to
a greater degree), resulting in the release of SCFA [9,24].
SCFA may be absorbed in the colon and help to provide a
reduced intake of calories and could result in a subse-
quent prolongation of satiety [10,25,26]. Jenkins et al.
[23,27]. reported that the consumption of viscous fiber
may also slow gastric emptying and small intestinal
Mean daily body weight (g) of male and female rats administered PGX® Figure 2
Mean daily body weight (g) of male and female rats administered PGX®.
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absorption of carbohydrates, resulting in reduced post-
prandial insulin secretion as well as lower LDL cholesterol
and apolipoprotein B concentrations. Research has found
that consumption of glucomannan and sodium alginate
decreases serum total, HDL and LDL cholesterol in
human trials [28,29]; however, it was determined that
these changes are modulated by increased fecal steroid
excretion and not increased cholesterol excretion [22].
Interestingly, in the present study, PGX increased ami-
notransferase levels in female rats, although glucoman-
nan has been shown to reduce increased aminotransferase
levels in rats fed a high cysteine diet [30]. Conversely, the
male rats that consumed 5.0% PGX showed a nonsignifi-
cant decrease in these enzyme levels. The changes in
aspartate (AST) and alanine (ALT) aminotransferase
enzyme levels found in the female rats did not correlate
with either histopathological changes to the liver mor-
phology or absolute or relative organ weight changes, nor
were the values double that of control, which is one indi-
cator of biological significance [31]. These low levels of
changes may be the result of an adaptive process to the
consumption of this viscous polysaccharide at the 5.0%
Table 2: Mean clinical biochemistry values of male rats administered PGX® for 90 days
Parameter (units) Control 1.25% 2.5% 5.0%
Aspartate Aminotransferase (U/L) 107 ± 32 82 ± 7 85 ± 15 92 ± 13
Alanine Aminotransferase (U/L) 50 ± 16 43 ± 7 46 ± 9 48 ± 7
Sorbitol Dehydrogenase (U/L) 8.4 ± 2.7 8.3 ± 3.0 8.2 ± 2.0 8.3 ± 2.0
Alkaline Phosphatase (U/L) 107 ± 30 112 ± 32 96 ± 13 113 ± 25
Total Bilirubin (mg/dL) 0.12 ± 0.01 0.12 ± 0.01 0.12 ± 0.02 0.13 ± 0.02
Blood Urea Nitrogen (mg/dL) 17 ± 2 18 ± 2 16 ± 1 17 ± 2
Creatinine (mg/dL) 0.31 ± 0.04 0.32 ± 0.03 0.32 ± 0.03 0.33 ± 0.03
Cholesterol (mg/dL) 99 ± 19 102 ± 25 100 ± 15 92 ± 11
Triglycerides (mg/dL) 36 ± 11 45 ± 19 44 ± 16 44 ± 10
Glucose (mg/dL) 115 ± 12 113 ± 5 113 ± 8 109 ± 8
Total Protein (g/dL) 6.2 ± 0.2 6.2 ± 0.2 6.2 ± 0.3 6.2 ± 0.2
Albumin (g/dL) 3.1 ± 0.2 3.1 ± 0.1 3.2 ± 0.1 3.3 ± 0.1a
Globulin (g/dL) 3.1 ± 0.2 3.0 ± 0.2 3.0 ± 0.2 2.9 ± 0.2
Calcium (mg/dL) 10.3 ± 0.3 10.3 ± 0.3 10.4 ± 0.3 10.7 ± 0.3
Inorganic Phosphorus (mg/dL) 6.9 ± 0.4 7.0 ± 0.7 7.1 ± 0.6 7.5 ± 1.0
Sodium (mmol/L) 144.2 ± 5.6 145.5 ± 4.8 145.0 ± 4.8 145.6 ± 6.2
Potassium (mmol/L) 5.39 ± 0.28 5.39 ± 0.4 5.44 ± 0.23 5.34 ± 0.46
Chloride (mmol/L) 102.4 ± 4.0 103.4 ± 3.3 102.9 ± 2.9 102.9 ± 4.1
aStatistically different from control (P ≤ 0.05) by Dunn's test
Table 3: Mean clinical biochemistry values of female rats administered PGX® for 90 days
Parameter (units) Control 1.25% 2.5% 5.0%
Aspartate Aminotransferase (U/L) 84 ± 13 86 ± 6 88 ± 10 101 ± 18a
Alanine Aminotransferase (U/L) 32 ± 3 38 ± 4 40 ± 7 54 ± 14a
Sorbitol Dehydrogenase (U/L) 10.0 ± 2.0 9.2 ± 1.7 10.3 ± 2.2 10.4 ± 2.0
Alkaline Phosphatase (U/L) 87 ± 31 97 ± 18 89 ± 25 103 ± 24
Total Bilirubin (mg/dL) 0.16 ± 0.03 0.16 ± 0.02 0.16 ± 0.02 0.18 ± 0.02
Blood Urea Nitrogen (mg/dL) 18 ± 2 17 ± 2 19 ± 1 18 ± 2
Creatinine (mg/dL) 0.41 ± 0.03 0.42 ± 0.04 0.44 ± 0.03 0.43 ± 0.04
Cholesterol (mg/dL) 98 ± 8 106 ± 11 102 ± 16 111 ± 13
Triglycerides (mg/dL) 25 ± 5 31 ± 8 29 ± 8 34 ± 8a
Glucose (mg/dL) 115 ± 8 111 ± 7 115 ± 10 111 ± 7
Total Protein (g/dL) 6.5 ± 0.3 6.5 ± 0.2 6.5 ± 0.3 6.4 ± 0.3
Albumin (g/dL) 3.5 ± 0.2 3.5 ± 0.2 3.5 ± 0.2 3.5 ± 0.2
Globulin (g/dL) 3.0 ± 0.2 3.0 ± 0.2 3.1 ± 0.2 2.9 ± 0.2
Calcium (mg/dL) 10.7 ± 0.4 10.6 ± 0.3 10.5 ± 0.1 10.7 ± 0.4
Inorganic Phosphorus (mg/dL) 5.9 ± 0.5 5.5 ± 0.6 4.9 ± 0.4b 5.4 ± 0.7
Sodium (mmol/L) 143.5 ± 5.8 141.0 ± 6.9 143.4 ± 5.6 136.6 ± 5.1b
Potassium (mmol/L) 5.02. ± 0.28 4.88 ± 0.25 4.89 ± 0.25 4.71 ± 0.25b
Chloride (mmol/L) 104.9 ± 4.0 102.3 ± 5.1 104.8 ± 3.4 100.4 ± 3.b
a Statistically different from control (P ≤ 0.05) by Dunn's test; b Statistically different from control (P≤ 0.05) by Dunnett testNutrition Journal 2009, 8:1 http://www.nutritionj.com/content/8/1/1
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level of intake, and may be due to increased protein turn-
over [32]. Neither of these enzymes are liver-specific in
rats. Both enzymes are also found in skeletal and cardiac
muscle [33]. However, no skeletal or cardiac muscle
changes (histological or organ weight) were found in any
of the animals in the present study. Further, no other cor-
relating liver enzyme levels were affected. Sorbitol dehy-
drogenase is liver-specific in rats, but this liver enzyme
was not affected in either the males or females. In addi-
tion, alkaline phosphatase, a membrane-bound enzyme
with the highest activity in osteoblasts, biliary epithelium
and epithelial cells of the kidney and intestines was not
affected. The statistically significant changes in AST and
ALT were noted to reside just outside the tight standard
deviations, and thus appear to be of minimal clinical sig-
nificance. Therefore, these findings were not considered
toxicologically significant. The increase in triglyceride
concentrations in the females fed 5.0% PGX, although
unexpected, was not a part of a dose-response effect, and
did not correlate with an increase in cholesterol levels.
Decreased red blood cell count occurred in the high dose
males, while significant decreases in serum sodium,
potassium and chloride concentrations were observed in
the females fed 5.0% PGX. However, the decreased min-
Table 4: Mean ± SDc of urinalysis values of male and female rats administered PGX® for 90 days
Parameter (units) Control 1.25% 2.5% 5.0%
Males
Volume (mL) 3.0 ± 1.5 4.0 ± 1.7 6.3 ± 4.6 6.4 ± 3.3a
Specific Gravity 1.074 ± 0.02 1.060 ± 0.017 1.054 ± 0.025 1.045 ± 0.018b
pH 6.2 ± 0.3 6.4 ± 0.3 6.6 ± 0.3b 7.1 ± 0.5b
Urobilinogen (EU/dL) 0.6 ± 0.4 0.4 ± 0.4 0.4 ± 0.3 0.5 ± 0.4
Total Protein (mg/dL) 876+683 808 ± 279 745 ± 412 457 ± 346
Females
Volume (mL) 2.9 ± 3.3 4.0 ± 2.7 1.0 ± 1.0 6.8 ± 2.9a
Specific Gravity 1.055 ± 0.026 1.042 ± 0.017 1.070 ± 0.011 1.027 ± 0.008b
pH 6.0 ± 0.0 6.2 ± 0.4 6.1 ± 0.2 6.9 ± 0.2a
Urobilinogen (EU/dL) 0.3 ± 0.3 0.3 ± 0.3 0.4 ± 0.4 0.2 ± 0.0
Total Protein (mg/dL) 258 ± 245 196 ± 374 111 ± 66 61 ± 46a
aP ≤ 0.05 by Dunn's test; bP ≤ 0.05 by Dunnett/Tamhane-Dunnett test; cSD = standard deviation
Table 5: Mean organ weights of male and female rats that consumed PGX® for 90 days
Organ Control 1.25% 2.5% 5.0%
Males
Brain 1.98 ± 0.12 1.97 ± 0.06 2.00 ± 0.12 1.99 ± 0.10
Heart 1.42 ± 0.13 1.46 ± 0.09 1.41 ± 0.11 1.43 ± 0.10
Kidneys (paired) 3.09 ± 0.23 2.90 ± 0.20 2.91 ± 0.23 2.89 ± 0.21
Liver 11.11 ± 1.10 11.12 ± 0.89 11.62 ± 1.29 11.76 ± 0.68
Spleen 0.81 ± 0.15 0.76 ± 0.08 0.75 ± 0.07 0.81 ± 0.07
Testes (paired) 4.03 ± 0.32 4.04 ± 0.27 4.01 ± 0.25 4.08 ± 0.19
Adrenals (paired) 0.063 ± 0.008 0.058 ± 0.0101 0.061 ± 0.0101 0.061 ± 0.004
Epididymides 1.571 ± 0.123 1.596 ± 0.188 1.663 ± 0.219 1.739 ± 0.137
Thymus 0.314 ± 0.045 0.358 ± 0.061 0.322 ± 0.049 0.294 ± 0.080
Females
Brain 1.79 ± 0.14 1.88 ± 0.07 1.92 ± 0.13 1.88 ± 0.07
Heart 0.93 ± 0.09 0.97 ± 0.08 0.96 ± 0.07 0.93 ± 0.06
Kidneys (paired) 1.84 ± 0.09 1.86 ± 0.18 1.85 ± 0.13 1.78 ± 0.10
Liver 6.34 ± 0.58 6.70 ± 0.84 6.51 ± 0.40 6.50 ± 0.38
Spleen 0.62 ± 0.09 0.66 ± 0.13 0.64 ± 0.07 0.58 ± 0.07
Uterus 0.65 ± 0.16 0.77 ± 0.23 0.67 ± 0.19 0.66 ± 0.18
Adrenals (paired) 0.069 ± 0.009 0.071 ± 0.006 0.073 ± 0.010 0.073 ± 0.009
Ovaries 0.118 ± 0.024 0.129 ± 0.029 0.140 ± 0.048 0.135 ± 0.042
Thymus 0.219 ± 0.0411 0.250 ± 0.061 0.254 ± 0.049 0.253 ± 0.054
1Mean and standard deviation for 9 animalsNutrition Journal 2009, 8:1 http://www.nutritionj.com/content/8/1/1
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eral concentrations may be the result of significantly
increased urinary volume in both males and females at
the high dose, with a concomitant decrease in urinary spe-
cific gravity (males and females) and protein concentra-
tion (females). The diet was provided in powder form,
and the high oral viscosity of PGX may have increased
water intake, thereby resulting in the lower red blood cell
count and lower plasma mineral levels. These results were
within historical control values, did not correlate with any
histopathological changes, and were not considered
adverse.
PGX is a highly purified, water soluble, viscous polysac-
charide product. The overall benefits and physiologic
effects of a soluble polysaccharide to human health are
directly proportional to its structural, chemical and phys-
ical properties [20], specifically, viscosity [23]. Viscous
gums increase stool volume and bulk, partially through
increased water retention and adsorption of organic mate-
rials [18,21]. Eastwood et al. [34] found that high levels of
xanthan gum administered to men (n = 5) for 23 days had
no significant effect on many parameters, including
plasma biochemistry, hematology, urinalysis parameters,
glucose, triglycerides, phospholipids, or HDL cholesterol,
although daily fecal bile was significantly increased. A
recent clinical trial found that PGX administered to sub-
jects for 21 days did not result in adverse effects, but did
decrease serum cholesterol [35]. The highest treatment
dose in this current study found decreased serum sodium,
potassium, and chloride levels in the female rats. These
effects may be related to the increased urine volume
observed, which could also account for the increase the
urine pH and decrease the specific gravity found in both
the male and female rats. Similar, though more excessive,
urine changes were noted in mice that consumed high lev-
els of sodium alginate (25% of the diet) for 89 weeks, and
were found to be reversible upon cessation of the diet
[36]. The changes in the high dose group were within his-
torical control values, and the low variability between the
animals may have contributed to the statistical signifi-
cance of these changes.
The observed effects of this study have been reported in
previous high dose studies of similar substances in rats,
and can be explained in terms of the predictable physio-
logical adaptive response to a high level of both indigest-
ible and fermentable dietary fibers [21,36,37]. In the
present study, no differences in any organ tissue under
histopathological analysis were observed between control
and treated animals, supporting the hypothesis that the
observed minimal clinical changes were adaptive in
nature and/or a result of the increased urinary volume.
Conclusion
In summary, administration of PGX to rats at up to 5.0%
of their diet (3219 and 3799 mg/kg bw/day in male and
female rats, respectively) for 90 days produced several uri-
nalysis and serum chemistry changes that were not corre-
lated histopathologically. These changes likely represent a
nutritional effect as the result of dietary displacement at
the high dose, and were not considered toxicological in
nature. Therefore, a NOAEL for PGX is at 5.0% of the diet,
corresponding to 3219 and 3799 mg/kg bw/day in male
and female rats, respectively.
Table 6: Mean organ-to-brain weight ratios of male and female rats that consumed PGX® for 90 days
Organ Control 1.25% 2.5% 5.0%
Males
Heart 0.72 ± 0.06 0.74 ± 0.04 0.71 ± 0.05 0.72 ± 0.07
Kidneys (paired) 1.56 ± 0.11 1.47 ± 0.09 1.47 ± 0.17 1.45 ± 0.09
Liver 5.63 ± 0.58 5.64 ± 0.43 5.87 ± 0.96 5.90 ± 0.37
Spleen 0.41 ± 0.07 0.38 ± 0.04 0.37 ± 0.03 0.40 ± 0.03
Testes (paired) 2.04 ± 0.12 2.05 ± 0.12 2.02 ± 0.18 2.05 ± 0.15
Adrenals (paired) 0.032 ± 0.005 0.030 ± 0.005 0.031 ± 0.006 0.031 ± 0.003
Epididymides 0.795 ± 0.056 0.810 ± 0.090 0.833 ± 0.86 0.873 ± 0.073
Thymus 0.160 ± 0.029 0.181 ± 0.029 0.161 ± 0.017 0.148 ± 0.042
Females
Heart 0.52 ± 0.06 0.52 ± 0.05 0.50 ± 0.03 0.49 ± 0.04
Kidneys (paired) 1.03 ± 0.06 0.99 ± 0.08 0.97 ± 0.11 0.95 ± 0.06
Liver 3.56 ± 0.39 3.57 ± 0.39 3.42 ± 0.34 3.47 ± 0.26
Spleen 0.35 ± 0.06 0.35 ± 0.06 0.34 ± 0.05 0.31 ± 0.03
Uterus 0.37 ± 0.09 0.41 ± 0.13 0.35 ± 0.10 0.35 ± 0.09
Adrenals (paired) 0.039 ± 0.007 0.038 ± 0.003 0.039 ± 0.007 0.039 ± 0.005
Ovaries 0.066 ± 0.014 0.069 ± 0.015 0.074 ± 0.029 0.072 ± 0.021
Thymus 0.124 ± 0.025 0.133 ± 0.032 0.134 ± 0.028 0.135 ± 0.028Nutrition Journal 2009, 8:1 http://www.nutritionj.com/content/8/1/1
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